Compare QCRH & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QCRH | ABCL |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1996 | 2020 |
| Metric | QCRH | ABCL |
|---|---|---|
| Price | $106.56 | $11.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $98.25 | $8.40 |
| AVG Volume (30 Days) | 96.8K | ★ 7.8M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | ★ 11.62 | 10.91 |
| EPS | ★ 4.18 | N/A |
| Revenue | ★ $165,999,610.00 | $75,128,000.00 |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | $5.59 | $21.85 |
| P/E Ratio | $25.50 | ★ N/A |
| Revenue Growth | 20.72 | ★ 160.56 |
| 52 Week Low | $66.71 | $2.75 |
| 52 Week High | $106.68 | $11.07 |
| Indicator | QCRH | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 69.84 | 83.57 |
| Support Level | $93.70 | $3.38 |
| Resistance Level | $106.55 | N/A |
| Average True Range (ATR) | 1.95 | 0.74 |
| MACD | 0.13 | 0.62 |
| Stochastic Oscillator | 77.00 | 98.39 |
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.